Barcelona, Spain – November 20, 2026
Revolution Medicines has presented updated Phase 1/2 clinical trial results evaluating its investigational combination approach of RASONQUE® (daraxonrasib), gemcitabine and nab-paclitaxel for patients with first-line metastatic pancreatic ductal adenocarcinoma (PDAC). The updated findings were announced on November 19, 2026, and presented during a late-breaking oral session at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics 2026 in Barcelona, Spain. The results demonstrate encouraging response rates, durable disease control and a promising survival signal, supporting continued clinical evaluation of the combination in patients with treatment-naïve metastatic pancreatic cancer. The findings come from the company’s open-label RMC-GI-102 Phase 1/2 study and provide additional evidence for the development of RAS-targeted therapies in pancreatic cancer
Updated Phase 1/2 Trial Demonstrates Encouraging Clinical Outcomes
As of September 28, 2026, a total of 61 patients with previously untreated metastatic pancreatic adenocarcinoma had received RASONQUE at a dose of 200 mg in combination with gemcitabine and nab-paclitaxel (GnP). The updated analysis, based on a median follow-up of 18.3 months, demonstrated a confirmed objective response rate (ORR) of 60.7%, including complete responses in 8.2% of patients. The study also reported a disease control rate of 90.2%, indicating that most patients experienced tumour response or disease stabilisation during treatment. The median duration of response was 11.1 months, while median progression-free survival (PFS) reached 12.8 months. Additionally, the estimated 12-month overall survival rate was 76.6%. These findings provide an encouraging clinical signal for the combination, particularly in a cancer setting where treatment outcomes remain challenging. The company reported that the safety profile was consistent with the previously observed safety profiles of RASONQUE and the gemcitabine/nab-paclitaxel chemotherapy regimen.
RASONQUE Combination Advances RAS-Targeted Cancer Treatment
Daraxonrasib, marketed as RASONQUE®, is an oral RAS(ON) tri-complex inhibitor developed by Revolution Medicines to target active forms of RAS proteins involved in cancer growth and tumour progression. RAS signalling plays a significant role in pancreatic cancer development, making it an important target for therapeutic research. The combination evaluated in the study brings together daraxonrasib with gemcitabine and nab-paclitaxel, two established chemotherapy agents used in pancreatic cancer treatment. By combining targeted inhibition of RAS signalling with chemotherapy, researchers aim to improve tumour response and extend disease control. The company stated that the updated results build on earlier findings presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. The latest analysis includes additional patients and longer follow-up, offering a more mature assessment of treatment response and durability. However, these findings are from an early-stage clinical study and require confirmation through larger, controlled clinical trials before broader conclusions about clinical benefit can be established.
Phase 3 RASolute 303 Trial Supports Further Development
The updated Phase 1/2 findings support the ongoing Phase 3 RASolute 303 clinical trial, which is evaluating daraxonrasib as a monotherapy and in combination with gemcitabine and nab-paclitaxel against gemcitabine and nab-paclitaxel alone in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma. The Phase 3 programme is designed to further assess the treatment’s efficacy and safety and determine whether the early clinical findings can be reproduced in a larger patient population. Revolution Medicines also highlighted that the combination recently received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for this first-line metastatic pancreatic cancer setting, recognising its potential to address an important unmet medical need. The designation is intended to facilitate development and regulatory review; it does not represent FDA approval for this first-line use.The ENA 2026 presentation marks an important clinical development milestone for Revolution Medicines as it advances its RAS-targeted oncology portfolio. While the updated response and survival findings are encouraging, further Phase 3 evidence will be essential to establish the combination’s potential role in first-line metastatic pancreatic cancer treatment.
Source: Revolution Medicines press release



